02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
22:28 , Jul 2, 2019 |  BC Extra  |  Company News

July 2 Company Quick Takes: Gilead's Truvada REMS removed; plus UC, Amicus/Paragon and Iovance

FDA removes REMS for Truvada  FDA said it is eliminating the REMS for Truvada emtricitabine/tenofovir from Gilead Sciences Inc. (NASDAQ:GILD) and its four generics approved for pre-exposure prophylaxis (PrEP), which required manufacturers to provide educational...
23:27 , Jul 1, 2019 |  BC Extra  |  Company News

July 1 Company Quick Takes: Alnylam submits MAA for hepatic porphyria therapy; plus Sage, Amicus and PTC

Alnylam submits hepatic porphyria therapy MAA  Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) submitted an MAA to EMA for givosiran to treat acute hepatic porphyria. Last month, the biotech completed a rolling NDA for the subcutaneous RNAi therapeutic...
22:27 , Jun 14, 2019 |  BC Extra  |  Company News

Management tracks: Flatiron picks Unum’s Vasconcelles to succeed Abernethy; plus Quell, Lytix and more

Flatiron Health Inc. hired Michael Vasconcelles as CMO. Vasconcelles, who was CMO of Unum Therapeutics Inc. (NASDAQ:UMRX), succeeds Amy Abernethy, who left to join FDA as principal deputy commissioner early this year. The Roche (SIX:ROG;...
18:51 , May 31, 2019 |  BC Extra  |  Financial News

May 31 Financial Quick Takes: Mabpharm prices Hong Kong IPO; plus follow-ons from Amicus, Myovant and more

Mabpharm down in first day of Hong Kong trading  Mabpharm Ltd. (HKSE:2181) lost HK$0.29 to HK$1.21 in its first day of trading Friday after raising HK$1.2 billion ($149.7 million) in a Hong Kong IPO Thursday...
21:53 , May 29, 2019 |  BC Extra  |  Company News

Amicus bolsters rare disease gene therapy pipeline with expanded UPenn deal

Amicus has added three more rare disease gene therapy programs to its pipeline through an expansion of its deal with the University of Pennsylvania, with the option to add at least a dozen more. The...
21:44 , Feb 12, 2019 |  BC Extra  |  Company News

Management tracks: Sanofi, Alexion, bluebird

Sanofi (Euronext:SAN; NASDAQ:SNY) said Ameet Nathwani will become the pharma's first chief digital officer in addition to his current role of EVP, CMO. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said SVP, Business Development and Corporate Strategy Aradhana...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
19:53 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Entrada raises $59M series A to take intracellular biologic into clinic

Entrada Therapeutics Inc. (Boston, Mass.) emerged from stealth Dec. 18 after raising $59 million in a series A round intended to propel its first intracellular biologics program into clinic. Intracellular targets have proven challenging for...